Tumors with KDM6A mutations tend to have fewer tumor-infiltrating lymphocytes (especially CD8+ T cells) and a microenvironment skewed toward immune tolerance (Chen et al., 2021a). This evidence concerns the gene KDM6A and neoplasm.